Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) Invested Capital (2016 - 2025)

Utah Medical Products has reported Invested Capital over the past 16 years, most recently at $119.3 million for Q4 2025.

  • Quarterly results put Invested Capital at $119.3 million for Q4 2025, up 1.57% from a year ago — trailing twelve months through Dec 2025 was $119.3 million (up 1.57% YoY), and the annual figure for FY2025 was $119.3 million, up 1.57%.
  • Invested Capital for Q4 2025 was $119.3 million at Utah Medical Products, up from $118.3 million in the prior quarter.
  • Over the last five years, Invested Capital for UTMD hit a ceiling of $128.3 million in Q4 2023 and a floor of $104.9 million in Q1 2021.
  • Median Invested Capital over the past 5 years was $117.5 million (2024), compared with a mean of $116.3 million.
  • Biggest five-year swings in Invested Capital: increased 14.34% in 2023 and later fell 8.48% in 2024.
  • Utah Medical Products' Invested Capital stood at $107.1 million in 2021, then rose by 6.64% to $114.3 million in 2022, then grew by 12.3% to $128.3 million in 2023, then dropped by 8.48% to $117.4 million in 2024, then grew by 1.57% to $119.3 million in 2025.
  • The last three reported values for Invested Capital were $119.3 million (Q4 2025), $118.3 million (Q3 2025), and $117.5 million (Q2 2025) per Business Quant data.